These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24196959)

  • 21. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
    Hicks KO; Myint H; Patterson AV; Pruijn FB; Siim BG; Patel K; Wilson WR
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):560-71. PubMed ID: 17869669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
    Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
    Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity.
    Hart SN; Zhong XB
    Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):439-52. PubMed ID: 18433346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
    Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
    Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361.
    Wong WW; Jackson RK; Liew LP; Dickson BD; Cheng GJ; Lipert B; Gu Y; Hunter FW; Wilson WR; Hay MP
    Biochem Pharmacol; 2019 Nov; 169():113641. PubMed ID: 31541630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of NADPH - cytochrome P450 oxidoreductase induction by dexamethasone in the H4IIE rat hepatoma cell line.
    Riddick DS; Mullen Grey AK
    Can J Physiol Pharmacol; 2020 May; 98(5):267-274. PubMed ID: 31825663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.
    Hunter FW; Hsu HL; Su J; Pullen SM; Wilson WR; Wang J
    Mol Cancer Ther; 2014 Nov; 13(11):2501-14. PubMed ID: 25193512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.
    Patterson AV; Ferry DM; Edmunds SJ; Gu Y; Singleton RS; Patel K; Pullen SM; Hicks KO; Syddall SP; Atwell GJ; Yang S; Denny WA; Wilson WR
    Clin Cancer Res; 2007 Jul; 13(13):3922-32. PubMed ID: 17606726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.
    Foehrenbacher A; Secomb TW; Wilson WR; Hicks KO
    Front Oncol; 2013 Dec; 3():314. PubMed ID: 24409417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
    Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
    Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.
    Fitzsimmons SA; Workman P; Grever M; Paull K; Camalier R; Lewis AD
    J Natl Cancer Inst; 1996 Mar; 88(5):259-69. PubMed ID: 8614004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzymatic activation of indolequinone-substituted 5-fluorodeoxyuridine prodrugs in hypoxic cells.
    Jiho Y; Kurihara R; Kawai K; Yamada H; Uto Y; Tanabe K
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1304-1307. PubMed ID: 30975626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
    Patterson AV; Barham HM; Chinje EC; Adams GE; Harris AL; Stratford IJ
    Br J Cancer; 1995 Nov; 72(5):1144-50. PubMed ID: 7577460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NADPH-cytochrome P450 oxidoreductase from the chicken (Gallus gallus): sequence characterization, functional expression and kinetic study.
    Zhou X; Li M; Sheng C; Qiu X
    Comp Biochem Physiol C Toxicol Pharmacol; 2011 Jan; 153(1):53-9. PubMed ID: 20728568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
    Winn BA; Devkota L; Kuch B; MacDonough MT; Strecker TE; Wang Y; Shi Z; Gerberich JL; Mondal D; Ramirez AJ; Hamel E; Chaplin DJ; Davis P; Mason RP; Trawick ML; Pinney KG
    J Nat Prod; 2020 Apr; 83(4):937-954. PubMed ID: 32196334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. P450 oxidoreductase: genotyping, expression, purification of recombinant protein, and activity assessments of wild-type and mutant protein.
    Agrawal V; Miller WL
    Methods Mol Biol; 2013; 987():225-37. PubMed ID: 23475681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene.
    Chen L; Yu LJ; Waxman DJ
    Cancer Res; 1997 Nov; 57(21):4830-7. PubMed ID: 9354446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects on human cytochromes P450 by CRISPR/Cas9-induced genetic knockout of cytochrome P450 reductase and cytochrome b5 in HepaRG cells.
    Heintze T; Klein K; Hofmann U; Zanger UM
    Sci Rep; 2021 Jan; 11(1):1000. PubMed ID: 33441761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of NADPH-cytochrome P450 reductase on all-trans-retinoic acid efficacy and cytochrome P450 26A1 expression in human myeloid leukaemia HL-60 cells.
    Hu L; Lv JF; Zhuo W; Zhang CM; Zhou HH; Fan L
    J Pharm Pharmacol; 2016 Sep; 68(9):1193-202. PubMed ID: 27366899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19.
    Agrawal V; Huang N; Miller WL
    Pharmacogenet Genomics; 2008 Jul; 18(7):569-76. PubMed ID: 18551037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.